Tetratherix Expands Tetramatrix Platform with Precision Medicine Franchise
Tetratherix Limited (ASX: TTX) has announced the expansion of its Tetramatrix™ platform with the launch of a new precision medicine franchise. The initiative introduces STEPP, a polymer-based delivery system designed for nasal administration of complex therapeutic compounds such as GLP-1s, peptides, and hormones. The technology helps compounds remain stable and adhere to the nasal lining, enabling controlled release and improved absorption into the bloodstream without the need for injections.
The company has entered into an exclusive research and development agreement with US consumer health group Superpower Health Inc. Under the agreement, Tetratherix will receive an annual license fee of US$3 million for up to ten years. In addition, Superpower will purchase Tetramatrix polymer to support the development of nasal delivery products targeting longevity and metabolic therapies in the US market.
The precision medicine franchise complements Tetratherix’s existing portfolio in bone regeneration, tissue spacing, and tissue healing. The company also confirmed that key development milestones remain on track, including anticipated FDA approvals for its bone regeneration products in mid-2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Tetratherix Expands Tetramatrix Platform with Precision Medicine Franchise
Tetratherix Limited (ASX: TTX) has announced the expansion of its Tetramatrix™ platform with the launch of a new precision medicine franchise. The initiative introduces STEPP, a polymer-based delivery system designed for nasal administration of complex therapeutic compounds such as GLP-1s, peptides, and hormones. The technology helps compounds remain stable and adhere to the nasal lining, enabling controlled release and improved absorption into the bloodstream without the need for injections.
The company has entered into an exclusive research and development agreement with US consumer health group Superpower Health Inc. Under the agreement, Tetratherix will receive an annual license fee of US$3 million for up to ten years. In addition, Superpower will purchase Tetramatrix polymer to support the development of nasal delivery products targeting longevity and metabolic therapies in the US market.
The precision medicine franchise complements Tetratherix’s existing portfolio in bone regeneration, tissue spacing, and tissue healing. The company also confirmed that key development milestones remain on track, including anticipated FDA approvals for its bone regeneration products in mid-2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au